Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-β and prion peptides
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Cyclin-dependent kinase 5 (Cdk5) is a serine-threonine kinase important for different cellular processes. Involved in tau protein hyperphosphorylation and apoptotic neuronal death, two main neuropathological markers of Alzheimer's disease (AD) and Prion-related encephalopathies (PRE), Cdk5 also participates in cell cycle regulation. However, the precise relationship between cell cycle reactivation and Cdk5 dysregulation in AD and PRE remains unclear. To determine Cdk5 involvement in the triggering of an abortive cell cycle by amyloid-beta (Abeta) and prion (PrP) peptides, associated with AD and PRE pathogenesis, we examined the levels/activation of several cell cycle-associated proteins in cultured cortical neurons treated with Abeta1-40 and PrP106-126 peptides. Peptide treatments significantly increased Cdk4, phospho-retinoblastoma and proliferating cell nuclear antigen (PCNA) levels, whereas phospho-histone H3 remained invariable, suggesting cell cycle arrest before the M phase. Moreover, Abeta1-40 and PrP106-126 largely augmented the number of PCNA-immunoreactive cells with fragmented nuclei. The Cdk5 inhibitor roscovitine and the calpain inhibitor MDL28170 prevented the alterations in cell cycle markers induced by both peptides. The data obtained suggest that Abetaand PrP peptides induced neuronal cell cycle re-entry through a mechanism involving Cdk5 dysregulation. Therefore, cell cycle reactivation mediated by Cdk5 can underlie the neurodegenerative processes that occur in AD and PRE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Ectopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain
Busser, J., Geldmacher, D. S., & Herrup, K. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02801.1998 · Cited by 543
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511
The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease
Höglinger, G. U., Breunig, J. J., Depboylu, C., Rouaux, C., Michel, P. P., Alvarez-Fischer, D., Boutillier, A.-L., DeGregori, J., Oertel, W. H., Rakic, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611671104 · Cited by 276
Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo
Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0327 · Cited by 187
The cell cycle as a therapeutic target for Alzheimer's disease
Neve, R. L., & McPhie, D. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.005 · Cited by 92
Majd, S., Zarifkar, A., Rastegar, K., & Takhshid, M. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.04.050 · Cited by 51
Hernández‐Ortega, K., Ferrera, P., & Arias, C. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21301 · Cited by 35
Cited by
The Role of Cdk5 in Alzheimer’s Disease
Liu, S.-L., Wang, C., Jiang, T., Tan, L., Xing, A., & Yu, J.-T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9369-x · Cited by 269
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
Li, Z., Yin, B., Zhang, S., Lan, Z., & Zhang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115817 · Cited by 54
Study of the pathways involved in apoptosis induced by PI3K inhibition in cerebellar granule neurons
Torre, A. V. D. L., Junyent, F., Folch, J., Pelegrí, C., Vilaplana, J., Auladell, C., Beas-Zarate, C., Pallàs, M., Camins, A., & Verdaguer, E. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.03.027 · Cited by 11
“Furthermore, although previous studies point to the relevance of cell cycle re-entry in neuronal apoptosis in vivo and in vitro (Verdaguer et al., 2005; Neve and McPhie, 2006; Lopes et al., 2009; Zhang et al., 2010), PI3K inhibition did not increase the expression of classical cyclin proteins.”
Influential
Metadata
- Authors
- Lopes, J. P., Oliveira, C. R., & Agostinho, P.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 8
- Issue
- 1
- Pages
- 97-104
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W1982573845
- Cited by
- 65
- References
- 11
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.